Targeted therapies in breast cancer: Where are we now?

European Journal of Cancer

Volumn 44, Issue 18, 2008, Pages 2781-2790

  Di Cosimo, Serena ^a   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Breast cancer; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BEVACIZUMAB; BIBW 2992; CAPECITABINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; HEAT SHOCK PROTEIN 90; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4G; KI 67 ANTIGEN; KU 0059436; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHRONIC MYELOID LEUKEMIA; DIMERIZATION; DISEASE FREE SURVIVAL; DNA REPAIR; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOXIA; METASTASIS; ONCOGENE NEU; OSTEOLYSIS; OVERALL SURVIVAL; PATIENT SELECTION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN BINDING; RASH; RISK BENEFIT ANALYSIS; RNA TRANSLATION; STOMATITIS; THROMBOCYTOPENIA; TUMOR BIOPSY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, ERBB-2; SRC-FAMILY KINASES;

EID: 56949094800     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.026     Document Type: Article

References (90)

1. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344 11 (2001) 783-792
2. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 357 26 (2007) 2666-2676
3. Hanahan D., and Weinberg R. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Di Cosimo S., and Baselga J. Pharmacodynamic endpoints in primary breast cancer. Ann Oncol 18 9 (2007) ix21-ix23
5. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 2 (2001) 127-137
6. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306 5701 (2004) 1506-1507
7. Hudziak R.M., Schlessinger J., and Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84 20 (1987) 7159-7163
8. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
9. Yu D., and Hung M. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 11 19(53) (2000) 6115-6121
10. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS 89 10 (1992) 4285-4289
11. Tokuda Y., Ohnishi Y., Shimamura K., et al. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73 (1996) 1362-1365
12. Baselga J., Norton L., Albanell J., Kim Y.-M., and Mendelsohn J. Recombinant humanized anti-HER2 antibody (herceptinTM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58 13 (1998) 2825-2831
13. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 19 (2005) 4265-4274
14. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
15. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
16. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
17. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 9555 (2007) 29-36
18. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 355 26 (2006) 2733-2743
19. Lin N., Dieras V., and Paul D. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Annual Meeting Proceedings Part I. 18S (June 20 Supplment). J Clin Oncol 25 (2007) 1012
20. Kirsch D.G., and Hochberg F.H. Targeting HER2 in brain metastases from breast cancer. Clin Cancer Res 9 15 (2003) 5435-5436
21. Cristofanilli M., Boussen H., Ben Ayed F., et al. A phase II combination study of lapatinib (TYKERB) and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 100 1 (2006) S5 [abstract 1]
22. Wong K., Fracasso P., and Bukowski R. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. J Clin Oncol. 24 (2006) 3018
23. Mom C., Eskens F., Gietema J., et al. Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. ASCO Annual Meeting Proceedings Part I. 18S (June 20 Supplement). J Clin Oncol 24 (2006) 3025
24. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 2 (2002) 127-137
25. Franklin M.C., Carey K.D., and Vajdos F.F. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 4 (2004) 317-328
26. Baselga J., Cameron D., Miles D., et al. Objective response rate in a Phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (Pts) with HER2 positive metastatic breast cancer (MBC) which had progressed during trastuzumab therapy. J Clin Oncol 25 (2007) 1004 [meeting abstracts]
27. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 5670 (2004) 554
28. Bachman K.E., Argani P., Samuels Y., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3 8 (2004) 772-775
29. Lee J.W., Soung Y.H., Kim S.Y., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24 8 (2005) 1477-1480
30. Campbell I.G., Russell S.E., Choong D.Y., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64 21 (2004) 7678-7681
31. Levine D.A., Bogomolniy F., Yee C.J., et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11 8 (2005) 2875-2878
32. Philp A.J., Campbell I.G., Leet C., et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61 20 (2001) 7426-7429
33. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Nat Acad Sci 96 8 (1999) 4240-4245
34. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 5573 (2002) 1655-1657
35. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 5712 (2005) 1098-1101
36. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 9 (2002) 648-657
37. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 12 (2005) 988-1004
38. Engelman J.A., Luo J., and Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7 8 (2006) 606-619
39. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 1 (1997) 64-67
40. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer cell 7 6 (2005) 561-573
41. Bader A.G., Kang S., and Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103 5 (2006) 1475-1479
42. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 2 (2004) 117-127
43. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 12 (2004) 2336-2347
44. Braunstein S., Karpisheva K., Pola C., et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28 3 (2007) 501-512
45. O'Reilly K.E., Rojo F., She Q.-B., et al. MTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Res 66 3 (2006) 1500-1508
46. Di Cosimo S., Scaltriti M., Val D., et al. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. ASCO Meeting Abstracts 25 18 suppl. (2007) 3511
47. Yao J., Phan A., Chang D., et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). ASCO Annual Meeting Proceedings Part I. 18S (June 20 Supplement). J Clin Oncol 24 (2006) 4042
48. Carpenter J.T., Roche H., Campone M., et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 23 (2005) A564
49. Tabernero J., Rojo F., Burris H., et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol: a3007 (2005)
50. Baselga J., Semiglazov V., van Dam P., et al. Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer. San Antonio Breast Cancer Symp (2007) [abstract 2066]
51. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99 2 (2007) 167-170
52. Stauffer F, Garcia-Echeverirria C, Furet P, et al. Biochemical, cellular, and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series. In: American association for cancer research annual meeting; 2007 Apr 14-18; Los Angeles, Calif. Philadelphia (Pa); 2007 [abstract 269].
53. Martin G.S. The hunting of the Src. Nat Rev Mol Cell Biol 2 6 (2001) 467-475
54. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Ann Rev Cell Dev Biol 13 1 (1997) 513-609
55. Bromann P.A., Korkaya H., and Courtneidge S.A. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23 48 (2004) 7957
56. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 6835 (2001) 355-365
57. Avizienyte E., and Frame M.C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 17 5 (2005) 542-547
58. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13 (1997) 513-609
59. Yeatman T.J. A renaissance for SRC. Nat Rev Cancer 4 6 (2004) 470-480
60. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J., and Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97 3 (2006) 263-274
61. Muthuswamy S.K., Siegel P.M., Dankort D.L., Webster M.A., and Muller W.J. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14 1 (1994) 735-743
62. Verbeek B., Vroom T., Adriaansen-Slot S., Ottenhoff-Kalff A., Geertzema G., and Rijksen A. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180 4 (1996) 383-388
63. Guy C.T., Muthuswamy S.K., Cardiff R.D., Soriano P., and Muller W.J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 8 1 (1994) 23-32
64. Hiscox S., Morgan L., Green T., Barrow D., Gee J., and Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97 3 (2006) 263-274
65. Rosen N., Bolen J.B., Schwartz A.M., Cohen P., DeSeau V., and Israel M.A. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261 29 (1986) 13754-13759
66. Ottenhoff-Kalff A.E., Rijksen G., van Beurden E.A.C.M., Hennipman A., Michels A.A., and Staal G.E.J. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52 17 (1992) 4773-4778
67. Huang F., Reeves K., Han X., et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67 5 (2007) 2226-2238
68. Hennequin L.F., Allen J., Breed J., et al. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49 22 (2006) 6465-6488
69. Eastell R., Hannon R.A., Gallagher N., Clack G., Macpherson M., and Marshall A. The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males. J Clin Oncol 23 16 suppl. (2005) 3041 [meeting abstracts]
70. Tabernero J., Cervantes A., Hoekman K., et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J Clin Oncol 25 18 suppl. (2007) 3520 [meeting abstracts]
71. Ame J.-C., Rolli V., Schreiber V., et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274 25 (1999) 17860-17868
72. Schreiber V., Ame J.-C., Dolle P., et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277 25 (2002) 23028-23036
73. Yang Y.-G., Cortes U., Patnaik S., Jasin M., and Wang Z.-Q. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 23 21 (2004) 3872-3882
74. Schreiber V., Dantzer F., Ame J.-C., and de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7 7 (2006) 517-528
75. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly(ADP-Ribose) polymerase in oncology. Clin Cancer Res 13 5 (2007) 1383-1388
76. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 52 1 (2005) 109-118
77. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 7035 (2005) 917-921
78. Fong P., Spicer J., Reade S., et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. ASCO Annual Meeting Proceedings Part I 18S (June 20 Supplement). J Clin Oncol 24 (2006) 3022
79. Neckers L., Kern A., and Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol 14 11 (2007) 1204-1206
80. Zhang H., and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82 (2004) 488-499
81. Maloney A., and Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2 (2002) 3-24
82. Basso A.D., Solit D.B., Munster P.N., and Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21 8 (2002) 1159-1166
83. Neckers L. Effects of geldanamycin and other naturally occurring small molecule antagonists of heat shock protein 90 on HER2 protein expression. Breast Dis 11 (2000) 49-59
84. Chandarlapaty S., Scaltriti M., Baselga J., et al. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. ASCO Meeting Abstracts 25 18 Suppl. (2007) 10515
85. Modi S., Stopeck A., Gordon M.S., et al. Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). J Clin Oncol 24 18 (2006) 501 [meeting abstracts]
86. Miller K., Rosen L., Modi S., et al. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T). ASCO Annual Meeting Proceedings (Post-Meeting Edition) 18S June 20 Supplement. J Clin Oncol 25 (2007) 1115
87. Demetri G., George S., Morgan J., et al. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a Phase I trial. J Clin Oncol 25 18S (2007) 10024
88. Sorlie T., Perou C.M., Fan C., et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5 11 (2006) 2914-2918
89. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 7173 (2007) 1235-1239
90. Prodromou C., Panaretou B., Chohan S., et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 19 16 (2000) 4383-4392